Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YGR
|
|||
| Former ID |
DAP000256
|
|||
| Drug Name |
Cinacalcet
|
|||
| Synonyms |
Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperparathyroidism [ICD-11: 5A51; ICD-9: 252.02, 588.81] | Approved | [1], [2] | |
| Kidney disease [ICD-11: GC2Z] | Phase 3 | [1], [2] | ||
| Therapeutic Class |
Calcimimetics
|
|||
| Company |
Amgen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H22F3N
|
|||
| Canonical SMILES |
CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
|
|||
| InChI |
1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
|
|||
| InChIKey |
VDHAWDNDOKGFTD-MRXNPFEDSA-N
|
|||
| CAS Number |
CAS 226256-56-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10252916, 14828105, 17397638, 26746623, 46232233, 46506315, 49658855, 49831866, 50070910, 50125742, 50963794, 57348294, 87325440, 99460880, 113435046, 123094726, 124772063, 124893630, 126616831, 126659507, 126666798, 134337570, 134339698, 135182927, 135723717, 137004918, 139773348, 152049240, 152258881, 160647730, 160964348, 162202444, 163365899, 164161045, 164765368, 164826120, 165237999, 174528429, 175268532, 176484923, 178100343, 179117002, 184816362, 223536062, 223664882, 224084531, 226452146, 241053841, 242598530, 243678877
|
|||
| ChEBI ID |
CHEBI:48390
|
|||
| ADReCS Drug ID | BADD_D00469 ; BADD_D02434 | |||
| SuperDrug ATC ID |
H05BX01
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular calcium-sensing receptor (CASR) | Target Info | Agonist | [3] |
| Pathway Interaction Database | E-cadherin signaling in keratinocytes | |||
| Reactome | G alpha (q) signalling events | |||
| G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3308). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021688. | |||
| REF 3 | Clinical pipeline report, company report or official report of Amgen (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.